Helix Biopharma Corp.
HBP.TO
TSX
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.57% | -45.02% | 222.09% | 215.75% | 200.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.04% | -42.94% | 54.53% | 73.12% | 58.00% |
| Operating Income | 52.04% | 42.94% | -54.53% | -73.12% | -58.00% |
| Income Before Tax | 49.31% | 45.19% | -51.20% | -70.50% | -55.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 49.31% | 45.19% | -51.20% | -70.50% | -55.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.31% | 45.19% | -51.20% | -70.50% | -55.52% |
| EBIT | 52.04% | 42.94% | -54.53% | -73.12% | -58.00% |
| EBITDA | 52.05% | 42.96% | -54.72% | -73.32% | -58.13% |
| EPS Basic | 58.13% | 51.36% | -21.99% | -40.99% | -29.84% |
| Normalized Basic EPS | 58.03% | 51.28% | -22.01% | -41.28% | -29.81% |
| EPS Diluted | 43.21% | 36.62% | -41.24% | -61.54% | -29.84% |
| Normalized Diluted EPS | 58.03% | 51.28% | -22.01% | -41.28% | -29.81% |
| Average Basic Shares Outstanding | 34.51% | 24.38% | 22.20% | 17.83% | 14.40% |
| Average Diluted Shares Outstanding | 34.51% | 24.38% | 22.20% | 17.83% | 14.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |